Dr Reddys Laboratories Ltd News

Nifty Pharma index rallies 2% in weak market;Ipca, Dr Reddy's gain up to 6%

At 02:37 pm; Nifty Pharma, the sole gainer among sectoral indices, was up 1.8 per cent, as compared to 1 per cent decline in the Nifty 50.

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Kazakhstan authority imposes penalty of Rs 28.7 lakh on Dr Reddy's unit

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary. The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing. The order levies a penalty of KZT 17,597,212 (Rs 2.87 million), it added. "Based on our evaluation, there is no material impact on the financials, operations, or other activities of the company," the Hyderabad-based drug firm said.

Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab

Dr Reddy's Labs tanks over 3% after USFDA inspects Hyderabad API facility

Dr Reddy's Laboratories share price fell up to 3.2 per cent at Rs 1,175 per share on the BSE in Thursday's

USFDA issues seven observations to Dr Reddy's Hyderabad manufacturing plant

Dr Reddy's Laboratories Ltd on Tuesday said the US health regulator has issued a Form 483 with seven observations to its active pharmaceutical ingredient manufacturing facility in Bollaram, Hyderabad. "The US Food & Drug Administration (USFDA) today completed a GMP inspection at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad," Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing. The inspection was conducted from November 13-19, 2024, it added. "We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," the company said. As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Dr Reddy's earnings future uncertain beyond FY27, say analysts; stock up 3%

Indian pharmaceutical major, Dr Reddy's Laboratories share surged 3.1 per cent at Rs 1,312 a piece on the BSE in Wednesday's intraday deals

Dr Reddy's Q2 results: PAT falls 9.5% to Rs 1,342 cr on weak US demand

The company reported a 9.5 per cent fall in its consolidated net profit

Q2 results today: Titan, Mazagon, and Dr Reddy's among 63 to post earnings

Q2 results today, November 5: GAIL India, Oil India, Merger Paints, Mankind Pharma, and Saregama will be releasing their earnings report for the July-September quarter on Nov 5

Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%

Analysts expect Dr Reddy's Labs to report a single digit fall in profits with a double digit revenue growth

Buy or Sell? TCS, Maruti, HUL among 7 Nifty stocks trading in oversold zone

These 7 Nifty 50 stocks are seen trading with an RSI below 30; stocks trading in oversold zone need not necessarily bounce back immediately. Here are the key levels to watch out for.

Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w

Dr Reddy's completes acquisition of Haleon's global NRT portfolio

DRL's Swiss subsidiary completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group company

Dr Reddy's Laboratories completes acquisition of Haleon's NRT portfolio

Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global portfolio of consumer healthcare brands, outside of the US, in the Nicotine Replacement Therapy (NRT) category. Dr Reddy's Laboratories SA has completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group company. "We would like to inform you that acquisition has now been completed, and the company has made payment of upfront cash consideration of GBP 458 million," the Hyderabad-based drug major said in a regulatory filing. As part of the acquisition, Northstar Switzerland along with its wholly-owned subsidiaries North Star OpCo and North Star Sweden AB (Sweden) are now wholly-owned step-down subsidiaries of the company with effect from September 30, 2024, it added. The acquired portfolio consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia .

Congress vs Sebi chief Buch: Trading strategies in M&M, Pidilite, Wockhardt

After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.

Dr Reddy's gets USFDA's inspection report for Srikakulam-based API plant

Dr Reddy's Laboratories on Friday said it has received the establishment inspection report (EIR) from the US health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The US Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is close, the Hyderabad-based drug maker said in a statement. As per USFDA, VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. On June 7 this year, Dr Reddy's had stated that the US health regulator has issued Form 483 with four observations after inspecting its Srikakulam-based facility. Shares of the company on Friday ended 0.42 per cent down at Rs 6,669.75 apiece on the BSE.

Dr Reddy's declines 3% after China's regulator bans import of ADHD drug

Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.

MCX, Lupin, TechM, Trent among 5 F&O stocks to Buy ahead of August expiry

Granules, MCX, Colgate, Trent, Dr.Reddy's, Glenmark Pharma, Voltas, Lupin, Tech Mahindra, Coromandel International and Balrampur Chini among F&O stocks are holding a PCR in excess of 1, shows F&O data

Dr Reddy's Labs shares drop after US FDA gives VIA tag to Vizag facilities

Shares of Dr Reddy's Laboratories slipped up to 2 per cent at Rs 6,875.05 per share on the BSE in Monday's intraday trade